[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 24, 2002

New Bethesda Terminology and Evidence-Based Management Guidelines for Cervical Cytology Findings

Author Affiliations

Author Affiliation: Robert E. Fechner Laboratory of Surgical Pathology, University of Virginia Health System, Charlottesville.

JAMA. 2002;287(16):2140-2141. doi:10.1001/jama.287.16.2140

In women's health, a remarkable convergence of events in 2001 has produced new information and direction to foster systematic improvement in cervical cancer screening. The Atypical Squamous Cells of Undetermined Significance–Low-grade Squamous Intraepithelial Lesion (ASCUS-LSIL) Triage Study (ALTS), which is sponsored by the National Cancer Institute, has published several articles presenting long-awaited data regarding the utility of human papillomavirus (HPV) testing in the context of the most common forms of cytological abnormality.1-4 These data supported the effort to revise the Bethesda System terminology used for reporting results of cervical cytology screening. Both the new Bethesda terminology and the ALTS data directly influenced management guidelines produced by the American Society of Colposcopy and Cervical Pathology (ASCCP)–sponsored consensus conference.